The Effectiveness of Adding Multiple Intermittent High-dose Inhalations of Nitric Oxide to Standard Antibacterial Therapy in the Treatment of Pneumonia

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a multicenter, prospective randomized controlled trial. At least 2 but no more than 5 centers are expected to participate in the study. The primary objective is to test the hypothesis that the addition of high-dose inhaled nitric oxide therapy to standard treatment has a positive effect on the clinical course of pneumonia and the structure and function of cardiopulmonary system. Number of participants: 200, including the subproject NO-PNEUMONIA-CAP - 100 CAP participants, the subproject NO-PNEUMONIA-NP - 100 NP participants. Number of groups: 4 Inhalation of iNO at a dose of 200 ppm for 30 minutes under the control of methemoglobin level (no more than 5%) three times a day if the patient is allocated to the main group. The general course of iNO therapy will last until the pneumonia resolves, but no more than 7 days. Recording of vital signs and safety assessment will be carried out immediately before the initiation of NO therapy and every 15 minutes after its start (pulse, blood pressure, respiratory rate, SpO2, temperature, MetHb level).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• An established diagnosis of Nosocomial Pneumonia (NP) after cardiac surgery under cardiopulmonary bypass (CPB) or hospitalization for Community-acquired pneumonia (CAP).

• Spontaneous breathing.

• Age \> 18 years.

• Signed informed consent.

• Negative result of immunochromatographic Severe acute respiratory syndrome-related coronavirus 2 rapid antigen test on the day of diagnosis of pneumonia.

⁃ Diagnostic criteria for NP The diagnosis of NP is considered established when the number of points on the

⁃ Clinical Pulmonary Infection Score (CPIS) is greater than 6:

⁃ Diagnostic criteria for CAP:

⁃ Radiologically confirmed focal pulmonary opacity and at least 2 clinical symptoms and signs of the following:

• acute fever at the onset of the disease (t° \> 38.0°C);

• cough with sputum;

• physical signs (crepitus/fine rales, bronchial breathing, shortening of percussion sound);

• leukocytosis \> 10x109/l and/or left shift (\> 10%)

Locations
Other Locations
Russian Federation
Cardiology Research Institute Tomsk National Research Medical Center
RECRUITING
Tomsk
Contact Information
Primary
Tatiana P. Kalashnikova, MD, PhD
kalashnikova-t@mail.ru
+7 9138141664
Backup
Nikolay O. Kamenshchikov, MD, PhD
nikolajkamenof@mail.ru
+79138183657
Time Frame
Start Date: 2024-01-15
Estimated Completion Date: 2027-01-15
Participants
Target number of participants: 200
Treatments
Experimental: Main group with nosocomial pneumonia
Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
Active_comparator: Control group with nosocomial pneumonia
Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
Experimental: Main group with community acquired pneumonia
Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
Active_comparator: Control group with community acquired pneumonia
Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
Related Therapeutic Areas
Sponsors
Leads: Tomsk National Research Medical Center of the Russian Academy of Sciences

This content was sourced from clinicaltrials.gov